Bank of America’s Ligand Pharmaceuticals LGND Stock Holding History

Bank of America’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-12,503	Closed	-$813K	–	7067
2019 Q4	$813K	Buy	+12,503	New	+$836K	﹤0.01%	4639
2019 Q1	–	Sell	-8,015	Closed	-$679K	–	7271
2018 Q4	$679K	Buy	+8,015	New	+$854K	﹤0.01%	4715
2016 Q3	–	Sell	-40,075	Closed	-$2.98M	–	7239
2016 Q2	$2.98M	Hold	40,075	–	–	﹤0.01%	3273
2016 Q1	$2.68M	Buy	+40,075	New	+$2.44M	﹤0.01%	3319
2014 Q4	–	Sell	-11,381	Closed	-$334K	–	7828
2014 Q3	$334K	Sell	11,381 -24,045	-68%	-$798K	﹤0.01%	4938
2014 Q2	$1.38M	Buy	35,426 +15,388	+77%	+$624K	﹤0.01%	3717
2014 Q1	$841K	Sell	20,038 -801	-4%	-$33.4K	﹤0.01%	4088
2013 Q4	$684K	Sell	20,839 -3,366	-14%	-$110K	﹤0.01%	4469
2013 Q3	$654K	Buy	24,205 +9,618	+66%	+$271K	﹤0.01%	4375
2013 Q2	$340K	Buy	+14,587	New	+$262K	﹤0.01%	5120

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America's LGND Position: Q2 2026 in Review

Bank of America increased its Ligand Pharmaceuticals (LGND) stake by 7.9% in Q2 2026, buying an estimated $2.94M and bringing the position to 170,349 shares worth $53.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1641.

Bank of America first reported a position in LGND in Q2 2013 and has held it in 53 quarters since. The position peaked at $129M in Q3 2017. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Bank of America held 170,349 shares of Ligand Pharmaceuticals worth $53.8M as of Q2 2026.
Bank of America bought 12,484 Ligand Pharmaceuticals shares in Q2 2026, an estimated $2.94M.
Ligand Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #1641 holding.
Bank of America first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
Bank of America's Ligand Pharmaceuticals position peaked at $129M in Q3 2017.
417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.